Loading...
XSHE
002317
Market cap3.36bUSD
Jul 10, Last price  
29.54CNY
1D
10.02%
1Q
58.82%
Jan 2017
139.19%
IPO
212.52%
Name

Guangdong Zhongsheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002317 chart
P/E
91.05
P/S
9.95
EPS
0.32
Div Yield, %
0.74%
Shrs. gr., 5y
0.79%
Rev. gr., 5y
5.88%
Revenues
2.52b
+2.24%
326,896,741404,403,391484,305,049551,602,812640,714,827750,643,827886,433,2221,090,027,7021,308,516,5031,577,736,5931,692,485,8231,964,235,0002,361,506,4452,531,516,4391,895,823,5592,429,095,4632,676,151,6162,610,550,1202,467,418,3942,522,737,619
Net income
276m
P
31,882,31742,266,10274,384,148100,354,725131,510,099150,537,489181,511,701187,702,285224,562,071296,714,726414,369,021420,121,097435,648,316317,729,474-426,606,740277,631,101322,050,289263,273,180-299,157,112275,754,920
CFO
305m
-9.66%
17,907,33449,354,64572,858,784100,891,08791,719,57970,555,422142,379,371110,945,083100,595,091192,248,390338,282,194369,905,148326,781,984251,155,767138,932,206622,766,28863,069,779190,613,632337,842,262305,204,582
Dividend
May 29, 20250.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the entire lifecycle of drug development, from research and development to manufacturing and commercialization. Its product portfolio encompasses both traditional Chinese medicines (TCM) and modern chemical pharmaceuticals. The company's robust research and development initiatives are directed towards creating solutions for a wide array of health conditions, specifically targeting ophthalmological, cardiovascular, cerebrovascular, respiratory, digestive, diabetic, oncological, and age-related degenerative diseases. Established in 1979, the company maintains its primary operations from its headquarters in Dongguan, China.
IPO date
Dec 11, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT